Insulet (NSDQ:PODD) said today that it has assumed direct commercial operations in Europe for its Omnipod tubeless insulin pump.
The Billerica, Mass.-based company first announced it would part ways with its former European distributor, Ypsomed, in July last year. Insulet has since established a team of more than 100 employees to take care of distributing and selling its Omnipod system in Europe, the company reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet assumes direct commercial operations in Europe appeared first on MassDevice.